3-O-Acetyl-11-hydroxy-beta-boswellic acidCAS# 146019-25-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 146019-25-2 | SDF | Download SDF |
| PubChem ID | 134715236 | Appearance | Powder |
| Formula | C32H50O5 | M.Wt | 514.74 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3R,4R,4aR,6aR,6bS,8aR,11R,12S,12aR,14R,14aR,14bS)-3-acetyloxy-14-hydroxy-4,6a,6b,8a,11,12,14b-heptamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1H-picene-4-carboxylic acid | ||
| SMILES | CC1CCC2(CCC3(C(=CC(C4C3(CCC5C4(CCC(C5(C)C(=O)O)OC(=O)C)C)C)O)C2C1C)C)C | ||
| Standard InChIKey | GKZSILIAFXNPRA-GHQZQFNUSA-N | ||
| Standard InChI | InChI=1S/C32H50O5/c1-18-9-12-28(4)15-16-30(6)21(25(28)19(18)2)17-22(34)26-29(5)13-11-24(37-20(3)33)32(8,27(35)36)23(29)10-14-31(26,30)7/h17-19,22-26,34H,9-16H2,1-8H3,(H,35,36)/t18-,19+,22-,23-,24-,25+,26-,28-,29+,30-,31-,32-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. 3-O-Acetyl-11-hydroxy-beta-boswellic acid is the precursor of 3-O-acetyl-9, 11-dehydro-beta-boswellic acid(a 5-lipoxygenase inhibitor ). |
| Targets | LOX |
3-O-Acetyl-11-hydroxy-beta-boswellic acid Dilution Calculator
3-O-Acetyl-11-hydroxy-beta-boswellic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9427 mL | 9.7136 mL | 19.4273 mL | 38.8546 mL | 48.5682 mL |
| 5 mM | 0.3885 mL | 1.9427 mL | 3.8855 mL | 7.7709 mL | 9.7136 mL |
| 10 mM | 0.1943 mL | 0.9714 mL | 1.9427 mL | 3.8855 mL | 4.8568 mL |
| 50 mM | 0.0389 mL | 0.1943 mL | 0.3885 mL | 0.7771 mL | 0.9714 mL |
| 100 mM | 0.0194 mL | 0.0971 mL | 0.1943 mL | 0.3885 mL | 0.4857 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Isorhamnetin 3-robinobioside
Catalog No.:BCN8693
CAS No.:53584-69-3
- Notoginsenoside FP2
Catalog No.:BCN8692
CAS No.:1004988-75-3
- Beta-Hydroxyisovalerylshikonin
Catalog No.:BCN8691
CAS No.:7415-78-3
- Clematichinenoside AR
Catalog No.:BCN8690
CAS No.:761425-93-8
- Conicasterol
Catalog No.:BCN8689
CAS No.:76758-18-4
- Licochalcone E
Catalog No.:BCN8688
CAS No.:864232-34-8
- Licochalcone D
Catalog No.:BCN8687
CAS No.:144506-15-0
- Isopropyl ferulate
Catalog No.:BCN8686
CAS No.:59831-94-6
- Isolindleyin
Catalog No.:BCN8685
CAS No.:87075-18-1
- Glabrol
Catalog No.:BCN8684
CAS No.:59870-65-4
- Protohypericin
Catalog No.:BCN8683
CAS No.:548-03-8
- Huzhangoside B
Catalog No.:BCN8682
CAS No.:94795-70-7
- Clitorin
Catalog No.:BCN8695
CAS No.:55804-74-5
- 5,7,2',4'-Tetrahydroxy-8,3'-di(gamma,gamma-dimethylallyl)-isoflavanone
Catalog No.:BCN8696
CAS No.:141846-47-1
- Picropodophyllol
Catalog No.:BCN8697
CAS No.:3811-15-2
- Secologanoside
Catalog No.:BCN8698
CAS No.:59472-23-0
- Trillikamtoside R
Catalog No.:BCN8699
CAS No.:2098642-71-6
- Tangshenoside I
Catalog No.:BCN8700
CAS No.:117278-74-7
- Cinchonine hydrochloride
Catalog No.:BCN8701
CAS No.:5949-11-1
- Bryonamide B
Catalog No.:BCN8702
CAS No.:5942-25-6
- Isololiolide
Catalog No.:BCN8703
CAS No.:38274-00-9
- Xanthoangelol B
Catalog No.:BCN8704
CAS No.:132998-81-3
- 5,6,7,4'-tetrahydroxyisoflavone-6,7-di-O-beta-D-glucopyranoside
Catalog No.:BCN8705
CAS No.:1219001-04-3
- Trikamsteroside E
Catalog No.:BCN8706
CAS No.:952579-37-2
Urease inhibitory activities of beta-boswellic acid derivatives.[Pubmed:23351363]
Daru. 2013 Jan 2;21(1):2.
UNLABELLED: BACKGROUND AND THE PURPOSE OF THE STUDY: Boswellia carterii have been used in traditional medicine for many years for management different gastrointestinal disorders. In this study, we wish to report urease inhibitory activity of four isolated compound of boswellic acid derivative. METHODS: 4 pentacyclic triterpenoid acids were isolated from Boswellia carterii and identified by NMR and Mass spectroscopic analysis (compounds 1, 3-O-acetyl-9,11-dehydro-beta-boswellic acid; 2, 3-O-Acetyl-11-hydroxy-beta-boswellic acid; 3. 3-O- acetyl-11-keto-beta-boswellic acid and 4, 11-keto-beta-boswellic acid. Their inhibitory activity on Jack bean urease were evaluated. Docking and pharmacophore analysis using AutoDock 4.2 and Ligandscout 3.03 programs were also performed to explain possible mechanism of interaction between isolated compounds and urease enzyme. RESULTS: It was found that compound 1 has the strongest inhibitory activity against Jack bean urease (IC50 = 6.27 +/- 0.03 muM), compared with thiourea as a standard inhibitor (IC50 = 21.1 +/- 0.3 muM). CONCLUSION: The inhibition potency is probably due to the formation of appropriate hydrogen bonds and hydrophobic interactions between the investigated compounds and urease enzyme active site and confirms its traditional usage.
Workup-dependent formation of 5-lipoxygenase inhibitory boswellic acid analogues.[Pubmed:10978197]
J Nat Prod. 2000 Aug;63(8):1058-61.
Pentacyclic triterpenes from the 11-keto-boswellic acid series were identified as the active principal ingredients of Boswellia resin, inhibiting the key enzyme of leukotriene biosynthesis, 5-lipoxygenase (5-LO). Of the genuine boswellic acids hitherto characterized, 3-O-acetyl-11-keto-beta-boswellic acid, AKBA (1), proved to be the most potent inhibitor of 5-LO. In the course of purification of further boswellic acid derivatives from Boswellia resin, we observed the degradation of the natural compound 3-O-Acetyl-11-hydroxy-beta-boswellic acid (2) to the thermodynamically more stable product 3-O-acetyl-9, 11-dehydro-beta-boswellic acid (4). The metastable intermediate of this conversion, under moderate conditions of workup in methanolic solutions, was identified as 3-O-acetyl-11-methoxy-beta-boswellic acid (3). The novel artifactual boswellic acid derivatives inhibited 5-LO product formation in intact cells with different characteristics: 4 almost totally abolished 5-LO activity, with an IC(50) of 0.75 microM, whereas 3 and 9,11-dehydro-beta-boswellic acid (5), the deacetylated analogue of 4, were incomplete inhibitors. The data suggest that the conditions chosen for the workup of Boswellia extracts could significantly influence the potency of their biological actions and their potential therapeutic effectiveness.
